Načítá se...
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody-Drug Conjugates (ADCs) are a class of cancer therapeutics that combines antigen specificity and potent cytotoxicity in a single molecule as they are comprised of an engineered antibody linked chemically to a cytotoxic drug. Four ADCs have received approval by the Food and Drug Administratio...
Uloženo v:
| Vydáno v: | J Exp Clin Cancer Res |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5802061/ https://ncbi.nlm.nih.gov/pubmed/29409507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-017-0667-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|